Recently, 18F-NY104 diagnostic nuclear drug, the second-generation molecule in the global innovative integrated pipeline independently developed by Norroy, entered Ph0 clinical trials for the first time in a famous hospital in China, and has completed the administration of more than 10 patients.

Preparation of 18F-NY104 used the M1 multifunctional module developed by Norroy sub-brand Sunmao, with a single batch output of 500+mCi. This is also the first clinical drug synthesis of M1 module, after multiple batches of validation, the drug yield is stable, reliable quality, fully meet the routine clinical needs, and build a protective barrier for medical personnel.

At present, the first-generation molecule 68Ga-NY104 in this pipeline has completed Ph0 clinical studies of more than 100 patients with kidney cancer, obtained FDA clinical approval, and the IND application in China was officially accepted by CDE this month.

Several original pipelines are advancing together, and Norroy looks forward to bringing the Gospel of integrated nuclear drugs for theranostics to global patients as soon as possible.